Clinical Support Department of Shenzhen Yingchi Technology Co.,Ltd. In December 2023, Prof. Kai Yuan from Xidian University and Prof. Yifei Zhu from Hebei Medical University published a paper entitled “Electroencephalography microstates as novel functional biomarkers for insomnia disorder” in General Psychiatry (IF=11.9), the team collected daytime awake EEG data and Polysomnography (PSG) sleep data of patients with insomnia, which revealed that abnormal EEG microstates... Read more
Clinical Support Department of Shenzhen Yingchi Technology Co.,Ltd. Post Traumatic Stress Disorder (PTSD) is a mental disorder that delays the onset and persists for a long time after experiencing or witnessing one or more actual deaths, or receiving death, serious injury, or various threats. Acute symptoms of PTSD, including persistent invasive recall, avoidance of trauma-related stimuli,... Read more
Clinical Support Department of Shenzhen Yingchi Technology Co.,Ltd. Background introduction Major Depressive Disorder (MDD) is the most common mental illness, usually accompanied by cognitive dysfunction, including impairment of attention, memory and executive functions, seriously affecting patients' quality of life. Although drugs can relieve patients' depressive symptoms, they do not improve patients' cognitive function, and some... Read more
Clinical Support Department of Shenzhen Yingchi Technology Co.,Ltd. Children and adolescents, a stage of significant brain development and hormonal fluctuations, exhibit different TMS responses. This complexity extends into adulthood, where aging-related neurophysiological changes, such as cortical atrophy and changes in cortical excitability, further alter TMS responses. In the previous article, we summarized the impact of neurodevelopment... Read more
Date:Monday, Nov. 13 - Thursday, Nov. 16, 2023 CET Location:Düsseldorf, Germany Official Website:https://www.medica-tradefair.com/ YINGCHI Booth:9C54 With over 5,000 exhibitors from 66 countries and more than 81,000 visitors from all over the world, MEDICA in Düsseldorf is one of the largest medical B2B trade fairs in the world. As an old friend, YINGCHI will once again participate in MEDICA 2023.... Read more
In September 2023, YINGCHI M-Ultimate TMS received FDA approval for the treatment of major depressive disorder in adult patients, marking a significant milestone in the company's endeavor to provide safe and effective medical solutions. Moreover, YINGCHI M-Ultimate TMS is not only limited to clinical applications; it is also playing an essential role in advancing clinical... Read more
